Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05142722 · ClinicalTrials.gov registry record · Phase 3
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
A Phase 3 study, sponsored by NewAmsterdam Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,530
- Enrollment target
NCT05142722 is a Phase 3 study that has completed, run by NewAmsterdam Pharma. The registered enrollment target is 2,530 participants.
The verdict
NCT05142722, a Phase 3 study, has completed, sponsored by NewAmsterdam Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,530 participants
- Enrollment target
Study Summary
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy
Interventions
- DRUG Placebo
- DRUG Obicetrapib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,530 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2024-09-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05142722
The ClinicalTrials.gov registry entry for NCT05142722 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewAmsterdam Pharma, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05142722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05142722 about?
NCT05142722 is a clinical study titled "Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies". This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-loweri...
What is the current status of trial NCT05142722?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,530 participants. The study started on 2021-12-15. Estimated completion is 2024-09-26.
What interventions are being tested in trial NCT05142722?
The interventions under investigation include: Placebo (DRUG), Obicetrapib (DRUG).
Who is sponsoring clinical trial NCT05142722?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.